Metabolic Support of the Enterocutaneous Fistula Patient

ABSTRACT

Enterocutaneous fistula (ECF) is a challenging clinical problem with many etiologies; however, the most common cause is iatrogenic, complicating abdominal surgery. Advances in the overall care of the ECF patient have resulted in dramatic reductions in morbidity and mortality over the last five decades. A structured approach to the management of ECF has been shown to result in improved outcomes. Initial physiologic stabilization of the postoperative patient, focused on hemodynamic and fluid support as well as aggressive sepsis control are the critical initial maneuvers. Subsequent optimization of nutrition and wound care allows the patient to regain a positive nitrogen balance, and allow for healing. Judicious use of antimotility agents as well as advanced wound care techniques helps to maximize healing as well as quality of life, and prepare patients for subsequent definitive surgery.

KEYWORDS

Enterocutaneous fistula - nutrition - parenteral - metabolic support

REFERENCES

• 1 Irving M, White R, Tresadern J. Three years' experience with an intestinal failure unit.  Ann R Coll Surg Engl. 1985;  67(1) 2-5
• 2 Draus Jr J M, Huss S A, Harty N J, Cheadle W G, Larson G M. Enterocutaneous fistula: are treatments improving?.  Surgery. 2006;  140(4) 570-576 discussion 576-578
• 3 Visschers R G, Olde Damink S W, van Bekkum M, Winkens B, Soeters P B, van Gemert W G. Health-related quality of life in patients treated for enterocutaneous fistula.  Br J Surg. 2008;  95(10) 1280-1286
• 4 Teixeira P G, Inaba K, Dubose J et al.. Enterocutaneous fistula complicating trauma laparotomy: a major resource burden.  Am Surg. 2009;  75(1) 30-32
• 5 Trzeciak S, Dellinger R P, Abate N L et al.. Translating research to clinical practice: a 1-year experience with implementing early goal-directed therapy for septic shock in the emergency department.  Chest. 2006;  129(2) 225-232
• 6 Dellinger R P, Levy M M, Carlet J M International Surviving Sepsis Campaign Guidelines Committee et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.  Crit Care Med. 2008;  36(1) 296-327
• 7 Solomkin J S, Mazuski J E, Bradley J S et al.. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.  Clin Infect Dis. 2010;  50(2) 133-164
• 8 Berry S M, Fischer J E. Enterocutaneous fistulas.  Curr Probl Surg. 1994;  31(6) 469-566
• 9 Hedrick T L, Evans H L, Smith R L et al.. Can we define the ideal duration of antibiotic therapy?.  Surg Infect (Larchmt). 2006;  7(5) 419-432
• 10 Joyce M R, Dietz D W. Management of complex gastrointestinal fistula.  Curr Probl Surg. 2009;  46(5) 384-430
• 11 Schecter W P, Hirshberg A, Chang D S et al.. Enteric fistulas: principles of management.  J Am Coll Surg. 2009;  209(4) 484-491
• 12 Goverman J, Yelon J A, Platz J J, Singson R C, Turcinovic M. The “fistula VAC,” a technique for management of enterocutaneous fistulae arising within the open abdomen: report of 5 cases.  J Trauma. 2006;  60(2) 428-431 discussion 431
• 13 Gunn L A, Follmar K E, Wong M S, Lettieri S C, Levin L S, Erdmann D. Management of enterocutaneous fistulas using negative-pressure dressings.  Ann Plast Surg. 2006;  57(6) 621-625
• 14 Cro C, George K J, Donnelly J, Irwin S T, Gardiner K R. Vacuum assisted closure system in the management of enterocutaneous fistulae.  Postgrad Med J. 2002;  78(920) 364-365
• 15 Wainstein D E, Fernandez E, Gonzalez D, Chara O, Berkowski D. Treatment of high-output enterocutaneous fistulas with a vacuum-compaction device. A ten-year experience.  World J Surg. 2008;  32(3) 430-435
• 16 Fischer J E. A cautionary note: the use of vacuum-assisted closure systems in the treatment of gastrointestinal cutaneous fistula may be associated with higher mortality from subsequent fistula development.  Am J Surg. 2008;  196(1) 1-2
• 17 Bee T K, Croce M A, Magnotti L J et al.. Temporary abdominal closure techniques: a prospective randomized trial comparing polyglactin 910 mesh and vacuum-assisted closure.  J Trauma. 2008;  65(2) 337-342 discussion 342-344
• 18 Visschers R G, Olde Damink S W, Winkens B, Soeters P B, van Gemert W G. Treatment strategies in 135 consecutive patients with enterocutaneous fistulas.  World J Surg. 2008;  32(3) 445-453
• 19 Dudrick S J, Maharaj A R, McKelvey A A. Artificial nutritional support in patients with gastrointestinal fistulas.  World J Surg. 1999;  23(6) 570-576
• 20 Chapman R, Foran R, Dunphy J E, Foran R, Dunphy J E. Management of intestinal fistulas.  Am J Surg. 1964;  108 157-164
• 21 Lloyd D A, Gabe S M, Windsor A C. Nutrition and management of enterocutaneous fistula.  Br J Surg. 2006;  93(9) 1045-1055
• 22 Stanga Z, Brunner A, Leuenberger M et al.. Nutrition in clinical practice-the refeeding syndrome: illustrative cases and guidelines for prevention and treatment.  Eur J Clin Nutr. 2008;  62(6) 687-694
• 23 Paauw J D, Borders H, Ingalls N et al.. The incidence of PICC line-associated thrombosis with and without the use of prophylactic anticoagulants.  JPEN J Parenter Enteral Nutr. 2008;  32(4) 443-447
• 24 Marra A R, Opilla M, Edmond M B, Kirby D F. Epidemiology of bloodstream infections in patients receiving long-term total parenteral nutrition.  J Clin Gastroenterol. 2007;  41(1) 19-28
• 25 Fiel M I, Wu H S, Iyer K, Rodriguez-Laiz G, Schiano T D. Rapid reversal of parenteral-nutrition-associated cirrhosis following isolated intestinal transplantation.  J Gastrointest Surg. 2009;  13(9) 1717-1723
• 26 Bower R H, Cerra F B, Bershadsky B et al.. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial.  Crit Care Med. 1995;  23(3) 436-449
• 27 Schilling J, Vranjes N, Fierz W et al.. Clinical outcome and immunology of postoperative arginine, omega-3 fatty acids, and nucleotide-enriched enteral feeding: a randomized prospective comparison with standard enteral and low calorie/low fat i.v. solutions.  Nutrition. 1996;  12(6) 423-429
• 28 Heyland D K, Novak F, Drover J W, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence.  JAMA. 2001;  286(8) 944-953
• 29 Marik P E, Zaloga G P. Immunonutrition in critically ill patients: a systematic review and analysis of the literature.  Intensive Care Med. 2008;  34(11) 1980-1990
• 30 Lévy E, Frileux P, Cugnenc P H, Honiger J, Ollivier J M, Parc R. High-output external fistulae of the small bowel: management with continuous enteral nutrition.  Br J Surg. 1989;  76(7) 676-679
• 31 Teubner A, Morrison K, Ravishankar H R, Anderson I D, Scott N A, Carlson G L. Fistuloclysis can successfully replace parenteral feeding in the nutritional support of patients with enterocutaneous fistula.  Br J Surg. 2004;  91(5) 625-631
• 32 Nubiola-Calonge P, Badía J M, Sancho J, Gil M J, Segura M, Sitges-Serra A. Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output.  Lancet. 1987;  2(8560) 672-674
• 33 Scott N A, Finnegan S, Irving M H. Octreotide and postoperative enterocutaneous fistulae: a controlled prospective study.  Acta Gastroenterol Belg. 1993;  56(3-4) 266-270
• 34 Sancho J J, di Costanzo J, Nubiola P et al.. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula.  Br J Surg. 1995;  82(5) 638-641
• 35 Alvarez C, McFadden D W, Reber H A. Complicated enterocutaneous fistulas: failure of octreotide to improve healing.  World J Surg. 2000;  24(5) 533-537 discussion 538
• 36 Alivizatos V, Felekis D, Zorbalas A. Evaluation of the effectiveness of octreotide in the conservative treatment of postoperative enterocutaneous fistulas.  Hepatogastroenterology. 2002;  49(46) 1010-1012